Your session is about to expire
← Back to Search
Niraparib + Radiotherapy for Triple Negative Breast Cancer (UNITY Trial)
UNITY Trial Summary
This trial is testing Niraparib as a possible treatment for triple negative breast cancer.
UNITY Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowUNITY Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 37 Patients • NCT03207347UNITY Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I still have cancer after chemotherapy, or my tumor is at least 1.0 cm without chemotherapy.I have not had any other cancer in the last 5 years.I have a history of MDS or AML.I am 18 years old or older.I have not had cancer treatments for at least 2 weeks and any side effects have gone.I can swallow and keep down pills.I have scleroderma or systemic lupus erythematosus.I have no lasting side effects from previous treatments.I have never had radiation therapy on the same side breast or nearby lymph nodes.I haven't had a blood transfusion in the last 4 weeks.I have a known p53 gene mutation.You have had allergic reactions to similar drugs or ingredients to niraparib.I weigh less than 77kg or my platelet count is below 150,000.I am not pregnant and agree to avoid pregnancy during the study.I agree not to donate blood during and for 3 months after the study.I weigh at least 77kg and my platelet count is over 150,000.I have been on a stable dose of corticosteroids for at least 4 weeks.My breast cancer is small, has not spread to lymph nodes, and is triple negative. I had surgery after chemotherapy.I have severe anemia, low white blood cell count, or low platelet count from my last chemo.My breast cancer is triple-negative and has not spread to other parts of my body.I am willing to stop any cancer treatments like chemotherapy or immunotherapy 2 weeks before starting radiation therapy.I had surgery to remove my breast cancer and check the lymph nodes.I have never taken PARP inhibitors before.I have tumor left after surgery that wasn't removed, except at the chest wall or skin.I do not have any major health issues that could worsen due to the study.I had major surgery less than 3 weeks ago but have recovered from it.I am planning to receive radiation therapy to my breast or chest area after surgery.I have brain or spinal cord cancer spread.I haven't taken any colony-stimulating factors in the last 4 weeks.My organs are functioning well, as tested within the last 30 days.I agree to use birth control from the start of the study until 90 days after it ends.I am fully active and can carry on all my pre-disease activities without restriction.
- Group 1: Niraparib
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many participants have signed up for this medicinal trial?
"Affirmative. The clinicaltrials.gov website attests that this medical study, which was first made available on July 11th 2019, is actively recruiting subjects. A total of 20 participants must be enlisted from 2 different research centres."
Are there other precedents of Niraparib in clinical experimentation?
"Currently, there are 99 live trials investigating the effects of Niraparib. Of those studies, 13 have reached Phase 3. Despite being based in Washington D.C., clinical sites across 2817 different locations are researching this treatment option."
Are there any vacant spots in this research program for potential participants?
"Affirmative, clinicaltrials.gov data affirms that this research endeavour is actively looking for participants, having been initially posted on July 11th 2019 and recently updated October 27 2021. Two sites are currently recruiting 20 people in total."
Is this trial a pioneering attempt for its type?
"Research into niraparib began in 2016 with the first trial sponsored by Myriad Genetics, Inc. After successful completion of this initial study on 733 participants, Niraparib gained phase 3 drug approval. At present time there are 99 active trials for it across 49 countries and 485 cities around the world."
Has the United States Food and Drug Administration sanctioned Niraparib?
"Due to the Phase 1 status, Niraparib is estimated to have a relative safety score of 1. This reflects the limited clinical data available for this medication regarding both efficacy and safety."
Share this study with friends
Copy Link
Messenger